Biotechnology company Inscripta raises $125M in series D round
Insight Weekly: US election scenarios; borrowing costs rise; commercial REIT fears
Street Talk | Episode 100 - KBW CEO offers optimism for bears fearful of bank liquidity, credit
Insight Weekly: Stocks endure more pain; bank branch M&A slows; debt ratios fall
Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall
Inscripta Inc. raised $125 million in its series D funding round, which was led by Paladin Capital Group.
New investors JS Capital Management LLC and Oak HC/FT Partners LLC participated in the round, alongside existing investors.
Inscripta has now raised a total of $259.5 million.
Inscripta is a Boulder, Colo.-based biotechnology company that is developing a benchtop platform for genome-scale engineering.
